Literature DB >> 7521399

Isolation, characterization, and expression of cDNA clones that encode rat UDP-galactose: ceramide galactosyltransferase.

N Stahl1, H Jurevics, P Morell, K Suzuki, B Popko.   

Abstract

UDP-galactose:ceramide galactosyltransferase (CGT) (EC. 2.4.1.62) catalyzes the final step in the synthesis of galactocerebroside (GalC), a glycosphingolipid found in high amounts in the myelin sheath. Here, the isolation of rat CGT specific cDNA clones is reported. The CGT sequence contains an open reading frame of 1,623 bp which predicts a protein of M(r) 61,126 Da. In transfection experiments the cDNA was found to confer CGT activity to Chinese hamster ovary cells. In rat brain the developmental expression pattern of CGT mRNA was similar to the myelination profile, whereas the sciatic nerve contained high amounts of CGT message over a long developmental period. CGT mRNA expression in the sciatic nerve was found to drop substantially following nerve injury and recover slowly when compared to the expression of mRNAs specific for the predominant myelin-specific proteins. The absolute amounts of CGT message in sciatic nerve and brain were found to be comparable to those that encode the structural proteins of myelin. Except for low amounts in the kidney, the CGT mRNA was not detected in other tissues examined. Southern blot analysis revealed that the CGT protein is likely encoded by a single, relatively large gene.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7521399     DOI: 10.1002/jnr.490380214

Source DB:  PubMed          Journal:  J Neurosci Res        ISSN: 0360-4012            Impact factor:   4.164


  17 in total

1.  Molecular cloning and characterization of galactosylceramide expression factor-1 (GEF-1).

Authors:  Kiyoshi Ogura; Tadashi Tai
Journal:  Neurochem Res       Date:  2002-08       Impact factor: 3.996

2.  Drastically abnormal gluco- and galactosylceramide composition does not affect ganglioside metabolism in the brain of mice deficient in galactosylceramide synthase.

Authors:  K Suzuki; M T Vanier; T Coetzee; B Popko
Journal:  Neurochem Res       Date:  1999-04       Impact factor: 3.996

Review 3.  Alterations in gene expression associated with primary demyelination and remyelination in the peripheral nervous system.

Authors:  A D Toews; J Hostettler; C Barrett; P Morell
Journal:  Neurochem Res       Date:  1997-10       Impact factor: 3.996

Review 4.  Biochemical, cell biological, pathological, and therapeutic aspects of Krabbe's disease.

Authors:  Je-Seong Won; Avtar K Singh; Inderjit Singh
Journal:  J Neurosci Res       Date:  2016-11       Impact factor: 4.164

Review 5.  Intra- and intercellular trafficking in sphingolipid metabolism in myelination.

Authors:  Binks W Wattenberg
Journal:  Adv Biol Regul       Date:  2018-11-23

Review 6.  Ceramide glycosylation catalyzed by glucosylceramide synthase and cancer drug resistance.

Authors:  Yong-Yu Liu; Ronald A Hill; Yu-Teh Li
Journal:  Adv Cancer Res       Date:  2013       Impact factor: 6.242

Review 7.  An overview of sphingolipid metabolism: from synthesis to breakdown.

Authors:  Christopher R Gault; Lina M Obeid; Yusuf A Hannun
Journal:  Adv Exp Med Biol       Date:  2010       Impact factor: 2.622

Review 8.  On the biogenesis of the myelin sheath: cognate polarized trafficking pathways in oligodendrocytes.

Authors:  H de Vries; D Hoekstra
Journal:  Glycoconj J       Date:  2000 Mar-Apr       Impact factor: 2.916

9.  A mammalian fatty acid hydroxylase responsible for the formation of alpha-hydroxylated galactosylceramide in myelin.

Authors:  Matthias Eckhardt; Afshin Yaghootfam; Simon N Fewou; Inge Zöller; Volkmar Gieselmann
Journal:  Biochem J       Date:  2005-05-15       Impact factor: 3.857

10.  Absence of oligodendroglial glucosylceramide synthesis does not result in CNS myelin abnormalities or alter the dysmyelinating phenotype of CGT-deficient mice.

Authors:  Laleh Saadat; Jeffrey L Dupree; John Kilkus; Xianlin Han; Maria Traka; Richard L Proia; Glyn Dawson; Brian Popko
Journal:  Glia       Date:  2010-03       Impact factor: 7.452

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.